Literature DB >> 8203860

In vitro antibacterial activity of AM-1155, a novel 6-fluoro-8-methoxy quinolone.

E Wakabayashi1, S Mitsuhashi.   

Abstract

The in vitro antibacterial activity of AM-1155 against a wide variety of clinical isolates was compared with those of other fluoroquinolones. The MICs of AM-1155 for 90% of Staphylococcus aureus, Streptococcus pneumoniae, and Enterococcus faecalis isolates tested were 0.10, 0.39, and 0.78 microgram/ml, respectively. The antibacterial activity of AM-1155 against gram-positive bacteria and anaerobes was comparable to those of sparfloxacin and tosufloxacin. AM-1155 inhibited 90% of most species of the family Enterobacteriaceae at a concentration of 0.39 microgram/ml. AM-1155 generally had activity comparable to that of sparfloxacin against gram-negative bacteria. AM-1155 showed moderate activity against methicillin- and quinolone-resistant S. aureus. AM-1155 demonstrated bactericidal activity at the MIC. The frequency of occurrence of spontaneous mutants resistant to four times the MIC of AM-1155 was < 1 x 10(9) for S. aureus, Escherichia coli, and Pseudomonas aeruginosa. AM-1155 strongly inhibited the supercoiling activities of DNA gyrases purified from E. coli and S. aureus.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8203860      PMCID: PMC284503          DOI: 10.1128/AAC.38.3.594

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  17 in total

1.  Mechanisms of clinical resistance to fluoroquinolones in Staphylococcus aureus.

Authors:  N Nakanishi; S Yoshida; H Wakebe; M Inoue; T Yamaguchi; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1991-12       Impact factor: 5.191

2.  In vitro and in vivo activity of NY-198, a new difluorinated quinolone.

Authors:  T Hirose; E Okezaki; H Kato; Y Ito; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1987-06       Impact factor: 5.191

3.  Comparative in vitro activity of a new quinolone, AM-1091.

Authors:  H C Neu; A Novelli; N X Chin
Journal:  Antimicrob Agents Chemother       Date:  1989-07       Impact factor: 5.191

4.  Purification and properties of DNA gyrase from a fluoroquinolone-resistant strain of Escherichia coli.

Authors:  K Sato; Y Inoue; T Fujii; H Aoyama; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1986-11       Impact factor: 5.191

5.  In vitro and in vivo antibacterial activities of T-3262, a new fluoroquinolone.

Authors:  K Fujimaki; T Noumi; I Saikawa; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1988-06       Impact factor: 5.191

6.  In vitro activity of AT-4140 against clinical bacterial isolates.

Authors:  T Kojima; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1989-11       Impact factor: 5.191

7.  Escherichia coli K-12 mutants resistant to nalidixic acid: genetic mapping and dominance studies.

Authors:  M W Hane; T H Wood
Journal:  J Bacteriol       Date:  1969-07       Impact factor: 3.490

8.  Incomplete cross-resistance of nalidixic and pipemidic acid-resistant variants of Serratia marcescens against ciprofloxacin, enoxacin, and norfloxacin.

Authors:  W H Traub
Journal:  Chemotherapy       Date:  1985       Impact factor: 2.544

9.  Purification of Citrobacter freundii DNA gyrase and inhibition by quinolones.

Authors:  H Aoyama; K Sato; T Fujii; K Fujimaki; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1988-01       Impact factor: 5.191

10.  In vitro and in vivo antibacterial activity of AM-833, a new quinolone derivative.

Authors:  K Hirai; H Aoyama; M Hosaka; Y Oomori; Y Niwata; S Suzue; T Irikura
Journal:  Antimicrob Agents Chemother       Date:  1986-06       Impact factor: 5.191

View more
  22 in total

1.  In vitro activities of gatifloxacin, two other quinolones, and five nonquinolone antimicrobials against obligately anaerobic bacteria.

Authors:  R Schaumann; G Ackermann; B Pless; M C Claros; A C Rodloff
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

2.  Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium.

Authors:  S Lober; S Ziege; M Rau; G Schreiber; A Mignot; P Koeppe; H Lode
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

3.  Activity of newer fluoroquinolones in vitro against gram-positive bacteria.

Authors:  G M Eliopoulos
Journal:  Drugs       Date:  1999       Impact factor: 9.546

4.  In vitro and in vivo activities of AM-1155, a new fluoroquinolone, against Chlamydia spp.

Authors:  N Miyashita; Y Niki; T Kishimoto; M Nakajima; T Matsushima
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

5.  Efficacy of gatifloxacin in experimental Escherichia coli meningitis.

Authors:  I Lutsar; I R Friedland; H S Jafri; L Wubbel; W Ng; F Ghaffar; G H McCracken
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

6.  Postantibiotic effects of gatifloxacin against gram-positive and -negative organisms.

Authors:  G A Pankuch; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

7.  The new fluoroquinolones: A critical review.

Authors:  G G Zhanel; A Walkty; L Vercaigne; J A Karlowsky; J Embil; A S Gin; D J Hoban
Journal:  Can J Infect Dis       Date:  1999-05

8.  Mechanisms and frequency of resistance to gatifloxacin in comparison to AM-1121 and ciprofloxacin in Staphylococcus aureus.

Authors:  D Ince; D C Hooper
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

9.  Single- and multiple-dose pharmacokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humans.

Authors:  M Nakashima; T Uematsu; K Kosuge; H Kusajima; T Ooie; Y Masuda; R Ishida; H Uchida
Journal:  Antimicrob Agents Chemother       Date:  1995-12       Impact factor: 5.191

10.  Antibacterial activity of gatifloxacin (AM-1155, CG5501, BMS-206584), a newly developed fluoroquinolone, against sequentially acquired quinolone-resistant mutants and the norA transformant of Staphylococcus aureus.

Authors:  H Fukuda; S Hori; K Hiramatsu
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.